To assess the perceptions of the Chinese frontline senior clinicians regarding coagulation-related events in patients with coronavirus disease 19 (COVID-19).

This survey assessed the perceptions of the Chinese clinicians regarding the coagulation function in patients with COVID-19 and the evaluation, diagnosis, and treatment of deep vein thrombosis (DVT) and acute pulmonary embolism (APE).

In 70 returned surveys, all respondents agreed that coagulation required attention. Most clinicians believed that COVID-19 patients should be routinely examined for coagulation indicators, with 100% and 92.86% of the doctors reporting a need to monitor patients in critical and severe conditions, respectively. Among the respondents, 75.71% believed the disseminated intravascular coagulation (DIC) score should be routinely measured, with 34.29% of whom preferring the 2017 Chinese DIC Scoring System (2017 CDSS). The DVT and APE incidence rates were＜5% among the patients treated by most of the doctors (84.29%, 82.86%, respectively). DVT assessment and screening were performed by 92.86% and 82.86% of the respondents respectively. Most respondents chose machinery and drugs for DVT prevention (60.00%), and low molecular-weight heparin for treatment(54.29%).

Most doctors believe that coagulation should be routinely monitored in COVID-19 patients, and assessment and treatment of DVT and APE should be standardized. Most respondents think the incidence of DVT and APE (＜5%) yet significant differences are noted in the clinicians' choice of DIC diagnostic criteria. The D-dimer level is a significant factor for assessing coagulation change in COVID-19 patients. However, the role of fibrinolytic processes in coagulation disorders with infectious diseases should be reconsidered.